Rhythm Pharmaceuticals Inc. has presented its long-term growth strategy, highlighting key developments in recent clinical trials and product demand. The company reported strong results from the Phase 3 trial of setmelanotide in acquired hypothalamic obesity and is on track to complete U.S. and EU regulatory submissions in the third quarter of 2025. Additionally, there is solid patient demand growth for IMCIVREE® (setmelanotide) in the first quarter of 2025, with a data readout for the Phase 2 trial of oral bivamelagon in acquired hypothalamic obesity expected in the third quarter of 2025. The company remains well-capitalized, with an expected cash runway extending into 2027. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。